• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

    2/3/26 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email

    Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples

    Sequencing connects decades of preserved biodiversity with the latest multiomic technologies

    SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom. Illumina will sequence up to 4,000 samples representing 1,300 species in the Frozen Zoo®. Genomic insights will be applied to real-world conservation challenges and efforts to safeguard animal species worldwide. A subset of samples will be used for groundbreaking multiomic research, geared toward unlocking vital insights into wildlife medicine, evolutionary biology, and biodiversity preservation.

    Illumina will sequence up to 4,000 samples representing 1,300 species in the Frozen Zoo®, in an agreement that connects the latest in genomics and multiomics with decades of preserved biodiversity.

    "Illumina is proud to partner with SDZWA to power the next era of the Frozen Zoo," said Cande Rogert, vice president and global head of Advanced Sciences at Illumina. "This collaboration is a wonderful example of the way multiomic technologies can activate the potential of these critical biodiversity biobanks."

    Conservation scientists across the globe are racing against time to collect samples from threatened and endangered species. Those samples are preserved in biobanks like the Frozen Zoo®, where they serve as a repository of increasingly fragile biodiversity. Sequencing those biobanked samples gives researchers genomic insights that are useful to help protect species and promote ecological resilience.

    "This collaboration marks a new era of genomic discovery that will accelerate our capacity to halt and reverse biodiversity loss," said Megan Owen, SDZWA's Benirschke Endowed Vice President of Conservation Science. "The next fifty years of the Frozen Zoo will rely on a global network of conservation scientists, as well as scalable multiomic technology to maximize the impact of biobanked samples."

    The San Diego Zoo Wildlife Alliance has partnered with the International Union for Conservation of Nature (IUCN) Species Survival Commission as a Center for Species Survival focused on biodiversity banking. The partnership with Illumina aims to illustrate the value of sequencing in conservation efforts globally. To make the effort possible, Illumina will generate whole-genome sequencing data from samples representing wildlife in the Frozen Zoo®, which will be made available for research to the San Diego Zoo Wildlife Alliance and its collaborators.

    A selection of the samples will be available for collaborative research projects, where Illumina's multiomic solutions will help conservation researchers unlock information about genetic diversity and population history. The collaboration will also help to validate multiomic workflows for conservation science, ensuring they perform reliably with non-human samples.

    "My father, Dr. Kurt Benirschke, founded the Frozen Zoo way back in 1975, believing it was important to preserve the DNA of rare and endangered species, but not knowing exactly why or how," said Rolf Benirschke, the board chair of the SDZWA Board of Trustees. "If he were alive today, he would be smiling knowing that his vision has led to this important collaboration with Illumina that will dramatically expand and amplify the science of conservation."

    Genomics insights are driving a deeper understanding of koala cancer risk

    Illumina collaborates with the San Diego Zoo Wildlife Alliance through its iConserve program and, in addition to the Frozen Zoo® collaboration, has also worked on lemur conservation in Madagascar and elephant genetic mapping in Africa. iConserve advances conservation by enabling projects with acute conservation needs and advocating for genomics as a conservation tool to support species protection and management decisions.

    One recent iConserve project, published last month in Nature Communications, demonstrates how sequencing koala genomes can inform conservation management decisions for koalas in zoos and in the wild. Koalas are susceptible to a retrovirus associated with cancers that are difficult for zoo veterinarians to detect and treat. Through the iConserve program, Illumina generated high-coverage whole-genome sequencing data for 91 San Diego Zoo koalas, from samples collected over multiple decades. Those sequences show how these viruses integrate into the koala genome across populations. This collaborative effort led to the identification of inherited and newly arising viral integrations in koala DNA. It also advanced the development of genetic risk scores, and the creation of a longevity breeding index—tools that can help reduce cancer risk and support healthier outcomes for koala populations in zoos and in the wild.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    About the San Diego Zoo Wildlife Alliance 

    San Diego Zoo Wildlife Alliance, a nonprofit conservation leader, inspires passion for nature and collaboration for a healthier world. The Alliance supports innovative conservation science through global partnerships and groundbreaking efforts at the world-famous San Diego Zoo and San Diego Zoo Safari Park, both leading zoological institutions and accredited botanical gardens. Through wildlife care expertise, cutting-edge science and continued collaboration, more than 44 endangered species have been reintroduced to native habitats. The Alliance reaches over 1 billion people annually through its two conservation parks and media channels in 170 countries, including San Diego Zoo Wildlife Explorers television, available in children's hospitals across 14 countries. Wildlife Allies—members, donors and guests—make success possible.

    About the San Diego Zoo Wildlife Alliance's Frozen Zoo® 

    The Frozen Zoo® is the world's first large-scale cryogenic biological bank dedicated to preserving living cells and reproductive material from wildlife—and remains the largest, most diverse collection of its kind. Founded in 1975 by Kurt Benirschke, M.D., the Frozen Zoo today holds over 11,500 samples from 4,000 unique individuals across 1,300 species. Stored in liquid nitrogen at minus 320 degrees Fahrenheit, the collection includes cells, embryos and gametes from mammals, birds, reptiles, amphibians, fish, plants, marine invertebrates and insects. The Frozen Zoo® is one of six unique San Diego Zoo Wildlife Alliance biobanking collections that make up its Wildlife Biodiversity Bank. Together these collections offer a variety of approaches to preserving biodiversity. Learn more at sdzwa.org/frozen-zoo.

    Contacts

    Illumina

    For media:

    Christine Douglass

    [email protected]

    San Diego Zoo Wildlife Alliance

    For media:

    Meghan Breen

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-the-san-diego-zoo-wildlife-alliance-partner-to-sequence-the-frozen-zoo-supporting-critical-conservation-genetics-efforts-globally-302676948.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ILMN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Illumina Inc.

    DEFA14A - ILLUMINA, INC. (0001110803) (Filer)

    4/9/26 4:18:50 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Illumina Inc.

    DEF 14A - ILLUMINA, INC. (0001110803) (Filer)

    4/9/26 4:16:45 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    4/2/26 9:09:56 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ullem Scott B.

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    4/2/26 6:32:26 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Meister Keith A.

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    4/2/26 6:31:06 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Technology Officer Barnard Steven was granted 7,603 shares, increasing direct ownership by 23% to 41,335 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    3/9/26 5:06:38 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Citigroup reiterated coverage on Illumina with a new price target

    Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

    3/4/25 8:10:42 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's

    4/9/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Announces Changes to Board of Directors

    David P. King nominated to support next phase of growth and innovation;Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the BoardSAN DIEGO, April 2, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced changes to its Board of Directors. Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, will retire from the Board in connection with the company's upcoming annual meeting of shareholders, and the Board has nominated David P. King to be elected as a member of the Board.  "On behalf of the entire Board and management team, I want t

    4/2/26 9:07:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

    SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need. "By deepening our collaboration, we'll continue to leverage the strengths of our resp

    3/18/26 9:15:00 AM ET
    $ILMN
    $LH
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's

    4/9/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

    Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:

    2/5/26 4:06:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

    SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info

    1/12/26 4:07:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components